Esbriet

July 26, 2017July 26, 2017

Pulmonary Fibrosis Therapy SM04646 Receives FDA Orphan Drug Designation

The U.S. Food and Drug Administration has granted orphan drug status to SM04646, San Diego-based Samumed‘s treatment for idiopathic pulmonary fibrosis. SM04646, which is delivered in a mist, could be approved as a ... Read more

July 24, 2017July 24, 2017

Real-world Safety of Ofev and Esbriet Matches Trial Reports, Despite Office Patients Older, Sicker

Idiopathic Pulmonary Fibrosis, News

Patients treated with Ofev (nintedanib) or Esbriet (pirfenidone) for pulmonary fibrosis in a real-world setting have similar rates of side effects as those reported in clinical trials testing the drugs, despite ... Read more

July 20, 2017July 20, 2017

Samumed Completes Phase 1 Study of Potential IPF Treatment with Positive Results

Idiopathic Pulmonary Fibrosis, News

Samumed has successfully completed a Phase 1 clinical trial in healthy individuals to evaluating a potential therapy — a nebulized inhalation solution called SM04646 — that treats idiopathic pulmonary fibrosis (IPF). The positive ... Read more

July 17, 2017July 17, 2017

Esbriet, Ofev Remain the Most Reliable Therapies for Idiopathic Pulmonary Fibrosis, Comparison Study Shows

Idiopathic Pulmonary Fibrosis, News

The first two approved therapies for idiopathic pulmonary fibrosis (IPF), Genentech’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib), are still the most reliable treatments among several approved and experimental therapies, according to a ... Read more

July 5, 2017July 5, 2017

Respiratory Hospitalization Rates May Improve Outcome Assessments in IPF Trials, Researchers Suggest

Idiopathic Pulmonary Fibrosis, News

Researchers at Columbia University propose that respiratory-related hospitalization rates are an important “patient-centered” outcome measure that should be considered in clinical trials assessing treatment effectiveness in patients with idiopathic pulmonary fibrosis (IPF), ... Read more

June 30, 2017June 30, 2017

New Esbriet Tablets for IPF Treatment Now Available in Europe

Idiopathic Pulmonary Fibrosis, News

The European Commission has approved a new formulation of Esbriet (pirfenidone) tablets for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). Esbriet, developed by Roche, is an oral antifibrotic medication approved ... Read more

June 16, 2017September 4, 2019

12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy

Idiopathic Pulmonary Fibrosis, Social Clips

Pulmonary fibrosis (PF) is a chronic and progressive lung disease where the air sac in the lungs (alveoli) becomes scarred and stiff making it difficult to breathe and get enough oxygen ... Read more

May 25, 2017May 25, 2017

Esbriet Subgroup Analyses Suggest Benefits Also in Moderate and Severe IPF

Idiopathic Pulmonary Fibrosis, News

Patients with more severe idiopathic pulmonary fibrosis (IPF) also benefit from Esbriet (pirfenidone) treatment, as do IPF patients with moderate lung function impairment, according to two studies presented at the ... Read more

May 16, 2017May 16, 2017

Genoa Pharmaceuticals Secures $62 Million in Funding to Evaluate Aerodone in IPF Treatment

Idiopathic Pulmonary Fibrosis, News

Genoa Pharmaceuticals has completed $62 million in a Series A financing round that secures funds for a Phase 2 clinical trial to evaluate Aerodone (inhaled pirfenidone) in treating diopathic pulmonary fibrosis ... Read more